Business
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct.
About this update from Mustang Bio, Inc.
[{"type":"text","content":"MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that results from the Waldenstrom macroglobulinemia (“WM”) cohort and other interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy being conducted at Fred Hutchinson Cancer Center (“Fred Hutch”), will be presented at the 11th International Workshop for Waldenstrom's Macroglobulinemia (“IWWM-11”) taking place in Madrid, Spain. MB-106 is being developed in a collaboration between Mustang and Fred Hutch to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). Details of the presentation are as follows: Title: CD20 CAR-T therapy for WM and other B-NHLsSession: Session XVI - Novel Treatment Approaches to WM-Clinical IIISession Date and Time: Saturday, October 29, 2022, 14:00-15:00 Central European Summer TimePresenter: Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington “We are very pleased with the advancement of the MB-106 clinical program which includes the recently announced multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating its safety and efficacy, the first MB-106 clinical trial under Mustang’s Investigational New Drug Application. Additionally, we are grateful that the Fred Hutch team continues to present compelling data from its ongoing Phase 1/2 clinical trial that demonstrate high efficacy and a favorable safety profile across CLL and B-NHLs including WM, a rare form of this cancer,” said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. “Finally, having been granted Orphan Drug Designation by the FDA for WM, we are looking forward to treating additional WM patients in the Mustang-sponsored Phase 1 portion of our trial in order to support a fast-to-market Phase 2 strategy for this indication.” As previously reported, highlights from the interim d...